Organization & Developments: BenevolentAI

Parents

*The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies
*The drug combo was swiftly given its own emergency authorization by the FDA for certain hospitalized patients.
*This spurred Lilly to kickstart a phase 3 trial in the summer, and by October the drug—in combination with Gilead’s repurposed Ebola med remdesivir—showed it could reduce time to recovery and improve clinical outcomes for patients with COVID-19 infection when compared to remdesivir on its own.
2021: In a study published in The Lancet early last year, the BenevolentAI team suggested a Lilly drug could not only reduce inflammation but also block the virus from entering and infecting lung cells by inhibiting a protein called AAK1.
2021: BenevolentAI_Fierce 15
2021: Once part of the now fallen Neil Woodford investment, BenevolentAI bounced back from the Woodford Equity Income fund collapse, nabbing a $90 million cash injection from Singaporean sovereign fund Temasek last year, coming two years after it raised $115 million from a number of undisclosed American investors.
2024: BenevolentAI pivots to 'TechBio' roots, causing more layoffs
2024: BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission